✨ Vonoprazan (CAS 881681-00-1) | High-Purity Potassium-Competitive Acid Blocker (P-CAB) ✨
🧪 Product Overview
Vonoprazan (CAS 881681-00-1) is a potent potassium-competitive acid blocker (P-CAB) with the molecular formula C₁₇H₁₆FN₃O₂S and a molecular weight of 345.39. This white to off-white crystalline powder (purity ≥98%) is designed for acid-related gastrointestinal disorder treatment, offering rapid and sustained suppression of gastric acid secretion. It reversibly inhibits H+/K+-ATPase in gastric parietal cells, outperforming traditional proton pump inhibitors (PPIs) with faster onset and longer efficacy.
Key Functions:
Treats gastroesophageal reflux disease (GERD) and peptic ulcers.
Enhances Helicobacter pylori eradication therapy outcomes.
Serves as a pharmaceutical intermediate for advanced formulations.
Target Industries: Pharmaceutical manufacturing, clinical research, and biotechnology.
⭐ Key Advantages
| 🔹 Ultra-High Purity | 🔹 Rapid Action | 🔹 Stability |
|---|
| ≥98% HPLC/EP-certified | Acid suppression within 30 minutes | Stable at -20°C, moisture-proof |
| Batch-specific COA | Duration up to 24 hours | 24-month shelf life |
🏭 Applications
GERD Management: Oral tablets for chronic acid reflux relief.
H. pylori Eradication: Combined with antibiotics for dual therapy.
Peptic Ulcer Therapy: Reduces recurrence rates in clinical settings.
Drug Development: Intermediate for novel P-CAB formulations.
📊 Quality Assurance
Testing Standards: Complies with USP/EP pharmacopeial guidelines.
Analytical Validation: HPLC, NMR, and LC-MS for identity and impurity profiling.
Certifications: ISO 9001 and GMP compliance for pharmaceutical-grade production.
📈 Market Insights
The global GERD treatment market is projected to reach $6.8 billion by 2030, driven by rising demand for non-PPI therapies and Asia-Pacific’s dominance in cost-efficient API manufacturing. Vonoprazan is increasingly adopted due to its superior pharmacokinetics and clinical efficacy.
China
